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Abstract
Purpose To evaluate the eVect of volume of cystectomies
in the Greater Amsterdam region on postoperative out-
comes.
Methods All primary bladder tumours diagnosed between
1989 and 2003 were selected from the Amsterdam Cancer
Registry, a population-based cancer registry (population
3.0 million). For all patients who underwent cystectomy
during 1989–2003 at 20 participating hospitals, medical
records were reviewed for information on postoperative
mortality, locoregional recurrences and relative risk of
death. To assess the eVect of volume, outcomes at an oncol-
ogy centre and low-volume hospitals were compared.
Results During 1989–2003 a total of 1,185 cystectomies
were performed in 20 hospitals of the Greater Amsterdam
region. Postoperative mortality was 3.2%. During 1989–
1997, 8% of cystectomies were performed at the oncology
centre, increasing to 30% in 1998–2003. Although postop-
erative mortality at this centre decreased from 4.0% in
1989–1997 to 1.1% in 1998–2003, the latter percentage
was not statistically signiWcantly diVerent from the other
hospitals during 1998–2003 (OR 0.3; P = 0.09). No statisti-
cally signiWcant diVerence in locoregional recurrence rate
and in the relative risk of death was observed between the
oncology centre and all other hospitals combined.
Conclusions We observed a lower postoperative mortal-
ity rate in the oncology centre compared to the low-volume
hospitals; however, this diVerence did not reach statistical
signiWcance. We could neither prove a statistically signiW-
cant relation between hospital volume, local recurrence rate
and survival after cystectomy. To answer the question if
centralisation of cystectomies is beneWcial more procedures
have to be compared.
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Introduction
Indicators of outcome after cystectomy (postoperative mor-
tality, recurrence rates and complications) have been com-
pared between high and low-volume surgeons and hospitals
in the USA. High-volume surgeons and high-volume hospi-
tals achieve superior outcomes after cystectomy for bladder
cancer patients [1–11]. However, deWnitions and thresholds
for high- and low-volume are not deWned, and vary from a
minimum of three to a minimum of ten. In the USA, the
regionalisation of cystectomies is encouraged by a coalition
of private and public purchasers of health insurance (Leap-
frog group), contrary to the Netherlands [9]. Almost all
studies on volume–outcome relation were performed in the
USA, and describe the postoperative mortality as indicator
of outcome.
This is the Wrst study in the Netherlands comparing vol-
ume and outcome after cystectomy for bladder cancer. In
recent years, a tendency to centralisation of cystectomies,
although no part of a consensus policy, has taken place in
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this centralisation we compared results of an oncology cen-
tre with other regional hospitals in the region of the Com-
prehensive Cancer Centre Amsterdam (CCCA).
Methods
Cancer registry data
All primary bladder tumours diagnosed and treated during
1989–2003 were selected from the CCCA Registry, a popu-
lation-based cancer registry with complete regional cover-
age (population 3.0 million). Patients treated with
cystectomy were compared with bladder cancer patients
treated with cystectomy at the oncology centre. As the
number of annual cystectomies in the oncology centre
raised from 7 to 21 between 1997 and 1998, this was
chosen as cut-oV point for comparison of two periods
(1989–1997 and 1998–2003). Registration clerks extracted
demographic data, morphology, stage (TNM) and primary
treatment from detailed hospital records. We converted all
TNM-data to the sixth version [12].
Follow-up of vital status
The vital status of all patients was updated by linking the
cancer registry to a Wle derived from the national Municipal
Population Registry Network comprising all legal Dutch
residents who had died or emigrated, as of 1 October 1994
until 1 February 2007. The vital status of patients dying
before 1 October 1994 was updated using electronic data
Wles, covering 1988–1994, which were made available by
the majority of municipal population registries and
included all deceased residents irrespective of the cause of
death. Completeness of follow-up of vital status is esti-
mated to approximate 100%.
Active follow-up after cystectomy
A subset of patients was deWned by selecting patients from
the cancer registry who underwent a cystectomy during
1989–2003. Data for 1989–1997 were collected in 2002.
For that period data from two small hospitals out of 20
could not be included because one hospital refused permis-
sion to extract data from the medical records and because
many patient Wles had been destroyed in the other. Data for
1998–2003 were collected in 2006. A supplementary data
set which was extracted from the medical records included
date of surgery, margins after surgery and the development
and date of locoregional recurrence (i.e. recurrence in the
soft tissue in the true pelvis). In the second period, the
occurrence of distant metastases was also collected in order
to be able to distinguish between isolated locoregional
recurrences and locoregional recurrence with concomitant
metastases.
Follow-up of after cystectomy was minimally 5 years for
patients treated until 2002 and minimally 4 and 3 years for
patients treated in 2002 and 2003, respectively.
Because active follow-up was not always done at the
oncology centre, we cannot guarantee that all recurrences in
patients with residence outside the region were known to
our registry. Therefore, patients referred to the oncology
centre but living outside of the CCCA region were not
included in the analysis of locoregional recurrence and sur-
vival after cystectomy.
Statistical methods
All statistics were performed in STATA, version 9.0. The
postoperative mortality was compared between the oncol-
ogy centre and all other hospitals using a Cox-regression
analysis, correcting for age groups (<60, 60–74, 75 years or
older) and sex. The relative risk of developing a locore-
gional recurrence and risk of death were analysed using a
Cox-regression model. The model included the following
variables: sex, morphology, T-stage, N-stage, margins, hos-
pital type and treatment period. Kaplan–Meier survival
curves were also calculated with STATA. Survival analysis
after local recurrence included only patients surviving a
minimum of 3 months after cystectomy.
Results
Centralisation and number of cystectomies per hospital
During 1989–2003, a total of 1,185 cystectomies were per-
formed in the 20 hospitals of the CCCA region. Table 1
shows that between 1989 and 1997 cystectomies were per-
formed in all hospitals, ranging from less than one to a
maximum of nine cystectomies/year. Between 1998 and
2003 three hospitals performed more than ten cystectomies/
year. The annual number of cystectomies in the oncology
centre increased from 7 (1989–1997) to 30 (1998–2003). In
the most recent years, the proportion of patients with resi-
dence in the CCCA region that undergoes cystectomy in the
oncology centre has further increased to about 30%.
Postoperative mortality
The postoperative mortality (·30 days after cystectomy)
for all hospitals combined was 3.2%, but ranged from 0
to almost 10% (Table 1). Between 1989 and 2003 the
postoperative mortality was 1.8% at the oncology centre
compared to 3.5% in all other hospitals combined123
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odds ratio (OR) 0.6; P = ns]. Between 1989 and 1997 post-
operative mortality in the oncological centre exceeded the
postoperative mortality in the other hospitals (4.0 vs. 2.9%;
OR 0.7; P = ns), while during 1998–2003 the percentage
decreased in the oncological centre to 1.1% compared to
4.4% in the other hospitals (OR 0.3; P = 0.09). The median
age in the oncology centre was signiWcantly lower than in
the low-volume hospitals (Table 1).
Locoregional recurrence
After exclusion of patients with residence outside the
CCCA region, stage 0 patients, salvage cystectomies and
cases with postoperative mortality, 926 patients remained
for the analysis of local recurrence: 122 patients were oper-
ated in the oncology centre and 804 in one of the other hos-
pitals (Table 2). 184 patients (19.9%) developed a
locoregional recurrence after cystectomy, including six,
more than 5 years after cystectomy. The vast majority
(91%) of recurrences occurred within 3 years after cystec-
tomy, 81% within 2 years. Of the patients who underwent
surgery during 1989–1997, 102 (21.2%) developed a loco-
regional recurrence. During 1998–2003, 82 (18.4%)
patients developed a locoregional recurrence (HR 0.7, 95%
CI 0.5–0.9), including 44 (9.9%) isolated locoregional
recurrences with no evidence of concomitant distant metas-
tases. Using the actuarial method to calculate the odds of
recurrence, the rates were 25% during 1989–1997 and 21%
during 1998–2003.
No statistically signiWcant diVerence in locoregional
recurrence rate was observed between the oncology centre
(18.9%) and all other hospitals combined (20%) (HR 0.9,
95% CI 0.5–1.4). In a sub-analysis of the second period
(1998–2003), we compared the risk of isolated locoregional
recurrence (i.e. in the absence of concomitant distant
metastasis) between various hospital types. In high-volume
hospitals (>10 cystectomies/year; three hospitals), interme-
diate volume (5–10; two hospitals) and low volume (<5; 13
hospitals) stratiWed for sex, morphology, T-stage, N-stage
Table 1 Number of cystecto-
mies and postoperative mortality 
according to hospital in the 
region of the Comprehensive 
Cancer Centre Amsterdam 
(CCCA) during 1989–2003
Hospital Number of cystectomies Postoperative 
mortality 
(%)
Median 
age (range)
1989–1997 1998–2003 Total
Low volume (<5 cystectomies/year)
A 20 7 27 – 68 (49–83)
B 3 5 8 – 69 (60–75)
D 6 – 6 – 70 (68–77)
E 7 4 11 – 65 (49–72)
F 46 25 71 2.8 65 (31–82)
G 42 29 71 7.0 70 (48–85)
H 38 28 66 – 70 (39–84)
I 20 35 55 9.1 65 (46–85)
J 21 13 34 2.9 69 (49–75)
L 10 10 20 – 69 (50–75)
M 18 – 18 – 69 (49–81)
N 23 5 28 3.6 63 (38–79)
O 12 6 18 – 66 (44–77)
S 29 25 54 3.7 65 (37–87)
T 43 23 66 – 61 (41–84)
Subtotal 338 215 553 2.8 67 (31–87)
Medium volume (5–10 cystectomies/year)
C 31 64 95 5.3 67 (31–87)
K 46 41 87 5.7 66 (43–88)
P 80 68 148 4.0 70 (41–93)
Q 52 25 77 2.6 62 (32–78)
Subtotal 209 198 407 4.4 68 (31–93)
High volume (>10 cystectomies/year)
Oncology centre 50 175 225 1.8 63 (30–80)
Total 597 588 1,185 3.2 66 (30–93)123
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rence was observed [>10 (reference) = 1; 5–10 h = 0.9;
<5 h = 0.8].
Survival after cystectomy
The 1-, 3- and 5-year survival after cystectomy was 79, 56
and 47%, respectively. 5-year survival after locoregional
recurrence was only 12%. In a multivariate Cox-regression
model, the following variables were independent prognosti-
cators for locoregional recurrence and relative risk of death:
T-stage, N-stage, margins, morphology and treatment period.
Discussion
Relation between volume and outcome
Many studies on the association of volume and outcome
after cancer surgery have been performed. In most of them,
the relation between volume and short term outcome is
strong and consistent, especially for high-risk cancer sur-
gery [6, 13, 14]. A recent study comparing hospital charac-
teristics between low- and high-volume hospitals in the
USA showed that diVerences in the processes of care play
an important role in postoperative mortality. Hospital
capacity, staYng level, clinical services, diagnostic and
interventional health services were at a considerably lower
level at low-volume hospitals as compared to high-volume
centres [7]. All these hospital-related diVerences inXuence
morbidity and postoperative mortality. Despite this evi-
dence, the underlying mechanisms of the volume outcome
relation still remain unclear [7, 9]. This is further illustrated
by Dutch studies comparing survival after surgery for
oesophageal and pancreatic cancer in low- and high-vol-
ume hospitals, showing contradictory results [15–17].
The minimum number of cystectomies one should per-
form to achieve the best outcome is diYcult to determine.
Neither the literature nor this study can answer this ques-
tion. In this study, the total number of cystectomies was
Table 2 Relative risk of locore-
gional recurrence following cys-
tectomy in patients with invasive 
bladder cancer in the region of 
Comprehensive Cancer Centre 
Amsterdam (CCCA) during 
1989–2003
Parameter Number of 
cystectomies
Locoregional 
recurrence (%)
Hazard ratio
Univariate 
(95% CI)
Multivariate 
(95% CI)
Sex
Males 722 19.7 1 (Ref.) 1 (Ref.)
Females 204 20.6 1.1 (0.8–1.6) 1.1 (0.8–1.6)
Morphology
Transitional cell ca. 844 19.4 1 (Ref.) 1 (Ref.)
Squamous cell ca. 39 12.8 0.5 (0.2–1.4) 0.4 (0.2–1.2)
Adenocarcinoma 26 34.6 1.8 (0.9–3.5) 1.5 (0.7–2.9)
UndiVerentiated ca. 17 35.3 2.7 (1.2–6.1)* 2.2 (1.0–5.0)
T-stage
T1 109 11.9 1 (Ref.) 1 (Ref.)
T2 410 13.9 1.2 (0.7–2.2) 1.2 (0.7–2.2)
T3 323 26.6 3.1 (1.7–5.5)* 2.9 (1.6–5.3)*
T4 84 33.3 4.7 (2.4–9.1)* 3.9 (2.0–7.7)*
N-stage
Negative 803 18.2 1 (Ref.) 1 (Ref.)
Positive 123 30.9 2.5 (1.8–3.6)* 2.0 (1.3–2.9)*
Margins
R0 813 18.5 1 (Ref.) 1 (Ref.)
R1 70 32.9 2.6 (1.7–4.1)* 1.8 (1.2–2.9)*
RX 43 25.6 2.4 (1.3–4.5)* 1.7 (0.9–3.2)
Hospital
Low-volume hospital 804 20.0 1 (Ref.) 1 (Ref.)
Oncology centre 122 18.9 1.0 (0.7–1.6) 0.9 (0.5–1.4)
Treatment period
1989–1997 481 21.2 1 (Ref.) 1 (Ref.)
1998–2003 445 18.4 0.8 (0.6–1.1) 0.7 (0.5–0.9)*
Total 926
R0 negative; R1 positive; 
RX unknown
* P < 0.05123
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ers have tried to determine the optimum caseload per sur-
geon. In the UK, an optimum cut-oV value of eight
cystectomies per year per surgeon was found [1]. However,
cut-oV values for low- and high-volume hospitals and sur-
geons seem arbitrary and vary in diVerent studies [1, 5, 8, 9,
11]. With a mortality rate between 0.5 and 5.5% and a mor-
bidity rate from 22 to 57%, cystectomy is considered a
high-risk procedure [18]. These Wndings have led to cen-
tralisation of such procedures in the USA [9, 19]. Although
no part of a consensus policy in the greater Amsterdam
region, there seems to be a tendency to centralisation, dem-
onstrated by the rise in the annual percentage of cystecto-
mies performed at the oncology centre in relation to the
total number of cystectomies. Especially between 1997 and
1998, the annual number of cystectomies rose from 7 to 21
and increased to 30 from that moment on. This swift
increase was the result of the expansion of the urology
department in the oncology centre. At this moment, 30% of
cystectomies in the Greater Amsterdam region and almost
10% of the total number of cystectomies in the Netherlands
is being performed at the oncology centre.
Postoperative mortality
We found an overall postoperative mortality of 3.2% in
range with most recent studies (0.5–5.5%) [9, 13, 14, 19–22].
Like in most studies, we observed a lower postoperative
mortality rate in the oncology centre compared to other
hospitals, especially in the second period of our study, after
an increase of annual cystectomies, although this diVerence
was not statistically signiWcant.
The median age at cystectomy was lower in the oncol-
ogy centre as compared to the other hospitals. While this
may cause better outcome Wgures, the relation between
age and postoperative mortality in cystectomy is not so
strong as compared to gastric and oesophageal cancer pro-
cedures [15–17]. Recently, May et al. [23] compared the
outcomes of patients younger than 75 years and older than
75 years at the time of cystectomy. They found no diVer-
ence in perioperative mortality [23]. Other reports con-
Wrm their Wndings [24, 25]. Comorbidity could be of
utmost importance [21]. However, in this population-
based comparison between the two hospital types comor-
bidity should not play a role, because one would expect
that comorbidity is equally distributed between all bladder
cancer patients in the CCCA region treated with cystec-
tomy. However, if selective referral of patients with more
comorbidity from community hospitals to the oncology
centre occurred (as we expect), then the postoperative
mortality would be higher in the centre. In contrast, the
postoperative mortality was lower in the centre as com-
pared to the community hospitals.
In three other hospitals also more than ten cystectomies/
year were performed, and these hospitals might be catego-
rised as high volume according to the literature [6]. In two
out of these three hospitals, postoperative mortality
remained the same during the whole study period. In the
oncology centre, a lower postoperative mortality was seen
for the second period when 30 cystectomies/year were per-
formed. Many changes were introduced at the oncology
centre after the Wrst period, including standardised postop-
erative care, direct postoperative enteral feeding and no
bowel preparation. Whether these changes are responsible
for the diVerence can only be assessed by in depth analysis
of hospital- and surgeon-related factors, which is beyond
the scope of this analysis.
Local recurrence and survival after cystectomy
DiVerences in deWnition of local recurrence make it hard to
compare recurrence rates between studies [26]. We found
an isolated local recurrence rate of 10% in range with most
reports (4–25%) [27, 28]. When we look at the overall local
recurrence rate with concomitant distant metastases, this
percentage was 19.7%. In patients with a T3 or T4 tumour,
the local recurrence rate was even higher, 26.6 and 33.3%,
respectively.
A 3% reduction in overall local recurrence rate was
observed between the Wrst and second periods (HR 0.7,
0.5–0.9). Perioperative chemotherapy (3.3% of patients
during 1989–1997; 6.5% of patients during 1998–2003)
might have inXuenced the risk of developing a local recur-
rence in our series. However, because only a few patients
(32 neoadjuvants, 14 adjuvants) received this treatment, no
separate analysis was possible.
In the second period, more patients with stage IV blad-
der cancer were treated with chemotherapy only instead of
cystectomy which might explain the lower locoregional
recurrence rate after cystectomy in the second period. Stage
migration between the Wrst and second periods might play
an additional role in the lower locoregional recurrence rate
in the second period. In the second period, the number of
stage III/IV patients increased due to better staging modali-
ties. When correcting the locoregional recurrence rate for
stage in the Cox-regression model, the overall (all stages)
recurrence rate decreased because of better stratiWcation in
the various stages.
We found no signiWcant diVerence between the oncology
centre and the other hospitals regarding the risk of develop-
ing local recurrence. When we compared low (<5 cystecto-
mies/year), intermediate (5–10 cystectomies/year) and
high-volume hospitals (>10 cystectomies/year), again no
signiWcant diVerence on local recurrence was observed.
In contrast to the comparison of short-term outcomes
after cystectomy, there is only one study that reports of the123
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term outcome. No signiWcant relation between urologist
(low volume) and urologic oncologist (high volume) and
risk of local recurrence after cystectomy was found [10].
One of the limitations of our study is that we do not have
information about the number of cystectomies per surgeon.
Volume-related diVerences in survival after cystectomy are
small compared to other cancer surgery, so large numbers
of patients are needed to Wnd a diVerence [6]. Just recently a
study was published comparing low- and high-volume hos-
pitals and survival after cystectomy. 5-year survival rates
after cystectomy between low- and high-volume hospitals
were 35 and 39%, respectively [6].
In theory, local recurrence and mortality might be good
indirect indicators of quality of surgery because they are
more likely to be dependent on the skills’ and experience of
the individual surgeon than on hospital-related factors [7].
Here again, with small diVerences, much larger number of
procedures have to be compared to Wnd statistically signiW-
cant diVerences. In our opinion, hospital-related factors
could be as important as surgeon-related factors in the case
of cystectomy. Moreover, these factors are related to each
other. This is underscored by the literature, showing higher
number of cystectomies being done in larger (semi)aca-
demic hospitals, having more technical and personal
resources.
Conclusion
We observed a lower postoperative mortality rate in the
oncology centre compared to the low-volume hospitals, but
this diVerence did not reach statistical signiWcance. We
could neither prove a statistical signiWcant relation between
hospital volume, local recurrence rate and survival after
cystectomy. More procedures have to be compared to prove
or refute the advantages of centralisation of cystectomy.
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